Five Prime Therapeutics Inc. (NASDAQ:FPRX) has been given an average recommendation of “Buy” by the eight brokerages that are covering the company. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $56.20.
A number of equities research analysts recently issued reports on FPRX shares. Credit Suisse Group AG reiterated a “buy” rating on shares of Five Prime Therapeutics in a research report on Tuesday, July 12th. Leerink Swann reiterated a “buy” rating and set a $45.00 target price on shares of Five Prime Therapeutics in a research report on Friday, July 15th. Jefferies Group set a $60.00 target price on shares of Five Prime Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 5th. Finally, Citigroup Inc. started coverage on shares of Five Prime Therapeutics in a research report on Tuesday, October 25th. They set a “buy” rating and a $65.00 target price for the company.
Shares of Five Prime Therapeutics (NASDAQ:FPRX) opened at 48.68 on Wednesday. Five Prime Therapeutics has a 1-year low of $28.01 and a 1-year high of $55.00. The company’s 50-day moving average is $50.58 and its 200 day moving average is $46.34. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 5.48 and a beta of 4.46.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.07. Five Prime Therapeutics had a net margin of 63.88% and a return on equity of 69.59%. The company earned $9.23 million during the quarter, compared to analysts’ expectations of $6.38 million. During the same quarter in the prior year, the company posted ($0.45) EPS. The business’s revenue was up 46.1% on a year-over-year basis. On average, analysts expect that Five Prime Therapeutics will post ($2.05) EPS for the current fiscal year.
In other Five Prime Therapeutics news, Director William R. Ringo sold 500 shares of the firm’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $52.00, for a total value of $26,000.00. Following the completion of the sale, the director now owns 500 shares in the company, valued at approximately $26,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.30% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. BlackRock Fund Advisors boosted its stake in Five Prime Therapeutics by 1.7% in the first quarter. BlackRock Fund Advisors now owns 944,434 shares of the company’s stock valued at $38,372,000 after buying an additional 15,566 shares during the last quarter. BlackRock Advisors LLC raised its position in shares of Five Prime Therapeutics by 6.1% in the second quarter. BlackRock Advisors LLC now owns 42,726 shares of the company’s stock valued at $1,767,000 after buying an additional 2,455 shares during the period. Adage Capital Partners GP L.L.C. raised its position in shares of Five Prime Therapeutics by 11.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,600,000 shares of the company’s stock valued at $105,638,000 after buying an additional 275,000 shares during the period. First Trust Advisors LP acquired a new position in shares of Five Prime Therapeutics during the second quarter valued at about $1,706,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Five Prime Therapeutics during the first quarter valued at about $411,000. Hedge funds and other institutional investors own 86.47% of the company’s stock.